Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prexasertib in Japanese patients with advanced solid tumors
NCT02514603Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of prexasertib in solid tumor, sponsored by Eli Lilly and Company. Primary endpoint: Dose-Limiting Toxicities. Started Oct 2015; status: completed.
02
Drugs
prexasertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02514603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514603.